Cancer detection with theranostic PET imaging
Part of Cancer clinical trials.
This trial uses a special PET scan called theranostic PET to find and track tumors in people with cancer. It may help guide treatment decisions by showing where the cancer is and how active it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your doctor has already ordered a PET scan using a theranostic tracer as part of your regular cancer care.
- You can lie flat and comfortably for the PET scan.
- You are able to understand and agree to the study.
- You are not pregnant, nursing, or breastfeeding.
- You are willing to follow the study procedures and return for follow-up if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether an investigational PET scan tracer is safe and tolerable when used for PET imaging in people with certain solid cancers. It mainly looks at side effects and how well the scan can be done, not whether it treats cancer.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
This trial uses a special PET/CT scan that targets a protein on some cancer cells to help detect and evaluate malignant tumors. It may help doctors better map tumors before any cancer treatment starts.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
Hear when a new Solid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.